Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved

• Autor(a) principal: Costa,Josiane Moreira da
• Data de Publicação: 2019
• Outros Autores: Moura,Cristiano Soares de, Pádua,Cristiane Aparecida Menezes de, Vegi,Aline Siqueira Fogal, Magalhães,Sérgia Maria Starling, Rodrigues,Marina Barra, Ribeiro,Andréia Queiroz
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista de Saúde Pública
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102019000100256
• topic: Anti-Bacterial Agents; Prescription Drug Overuse, legislation & jurisprudence; Drug Resistance, Microbial; Drug Monitoring; Pharmacovigilance

ABSTRACT OBJECTIVE To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.